Residual disease is the main, but not the only factor impacting satisfaction in psoriatic patients undergoing biological therapies

• Published in: International journal of dermatology 2024-10
• Main Authors: Caldarola, Giacomo, De Luca, Eleonora, Falco, Gennaro Marco, Di Nardo, Lucia, Bocchino, Enrico, D'Agostino, Magda, Peris, Ketty, De Simone, Clara
• Format: Article
• Language: English
• ISSN: 0011-9059; 1365-4632; 1365-4632
• DOI: 10.1111/ijd.17509

Despite advancements in psoriasis treatment, a gap remains in aligning patient satisfaction with clinical outcomes. Our study aimed to evaluate which clinical and psychological factors may impact treatment satisfaction in psoriatic patients undergoing long-term biological therapies. We performed an observational, cross-sectional, single-center study involving adult patients with moderate-to-severe psoriasis treated with biologics for at least 12 months. We collected sociodemographic characteristics and data on the course of the psoriasis. We also assessed the absolute (residual) Psoriasis Area and Severity Index (PASI), the site of the residual disease, and the severity of pruritus through the Visual Analogue Scale (VAS). Satisfaction was evaluated using the Treatment Satisfaction Questionnaire for Medication (TSQMv.II). The Type D Personality Scale (DS14 questionnaire and Patient Health Questionnaire-9 assessed the psychological profile. Overall, 146 patients were included, and 82.1% were globally satisfied (global satisfaction TSQM score >75). Linear regression analysis showed a negative correlation between global satisfaction scoring and residual PASI. The multivariable analysis found a higher VAS-pruritus score (OR = 1.20, 95% CI = 1.01-1.44; P = 0.043) and not reaching a residual PASI